Natera, Inc. (NASDAQ:NTRA) CFO Sells $59,068.64 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 496 shares of the business’s stock in a transaction dated Wednesday, October 23rd. The stock was sold at an average price of $119.09, for a total transaction of $59,068.64. Following the sale, the chief financial officer now directly owns 74,314 shares of the company’s stock, valued at $8,850,054.26. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, October 21st, Michael Burkes Brophy sold 608 shares of Natera stock. The stock was sold at an average price of $120.76, for a total transaction of $73,422.08.
• On Wednesday, July 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $99.65, for a total transaction of $185,946.90.
• On Monday, July 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $102.77, for a total transaction of $127,229.26.
• On Thursday, July 25th, Michael Burkes Brophy sold 690 shares of Natera stock. The shares were sold at an average price of $105.29, for a total transaction of $72,650.10.

Natera Stock Performance

Shares of NTRA stock opened at $119.17 on Friday. The firm’s 50 day moving average price is $123.37 and its 200-day moving average price is $111.09. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. Natera, Inc. has a one year low of $36.90 and a one year high of $133.54. The firm has a market cap of $14.74 billion, a P/E ratio of -48.64 and a beta of 1.53.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same period in the prior year, the business posted ($0.97) EPS. The business’s revenue for the quarter was up 58.1% compared to the same quarter last year. As a group, equities research analysts predict that Natera, Inc. will post -1.96 EPS for the current year.

Analyst Upgrades and Downgrades

NTRA has been the subject of several research reports. The Goldman Sachs Group upped their price objective on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Morgan Stanley upped their price objective on shares of Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. TD Cowen upped their price objective on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research note on Friday. Finally, BTIG Research increased their price target on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $124.44.

Institutional Investors Weigh In On Natera

A number of hedge funds have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC lifted its holdings in Natera by 17.8% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 10,858 shares of the medical research company’s stock worth $1,378,000 after buying an additional 1,640 shares in the last quarter. Lake Street Advisors Group LLC lifted its holdings in Natera by 7.4% during the 3rd quarter. Lake Street Advisors Group LLC now owns 2,250 shares of the medical research company’s stock worth $286,000 after buying an additional 156 shares in the last quarter. HWG Holdings LP lifted its holdings in Natera by 395.8% during the 3rd quarter. HWG Holdings LP now owns 14,920 shares of the medical research company’s stock worth $1,894,000 after buying an additional 11,911 shares in the last quarter. Zweig DiMenna Associates LLC lifted its holdings in Natera by 213.0% during the 3rd quarter. Zweig DiMenna Associates LLC now owns 242,625 shares of the medical research company’s stock worth $30,801,000 after buying an additional 165,100 shares in the last quarter. Finally, International Assets Investment Management LLC lifted its holdings in Natera by 9,755.3% during the 3rd quarter. International Assets Investment Management LLC now owns 14,980 shares of the medical research company’s stock worth $1,902,000 after buying an additional 14,828 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.